Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Receives $8.33 Consensus PT from Brokerages

by · The Cerbat Gem

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the five analysts that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $8.3333.

A number of brokerages recently commented on AUTL. Weiss Ratings reiterated a “sell (d-)” rating on shares of Autolus Therapeutics in a research note on Wednesday, October 8th. William Blair restated an “outperform” rating on shares of Autolus Therapeutics in a research report on Wednesday, September 24th. Wall Street Zen cut shares of Autolus Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Saturday, November 15th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $10.00 target price on shares of Autolus Therapeutics in a research note on Friday, December 12th.

Get Our Latest Stock Analysis on AUTL

Autolus Therapeutics Trading Up 4.8%

AUTL opened at $1.65 on Friday. Autolus Therapeutics has a 1-year low of $1.11 and a 1-year high of $2.80. The company has a market cap of $437.81 million, a P/E ratio of -1.98 and a beta of 2.01. The company has a fifty day moving average price of $1.48 and a two-hundred day moving average price of $1.80.

Autolus Therapeutics (NASDAQ:AUTL – Get Free Report) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.07). The business had revenue of $21.19 million during the quarter, compared to the consensus estimate of $21.08 million. Autolus Therapeutics had a negative net margin of 439.69% and a negative return on equity of 63.76%. On average, research analysts forecast that Autolus Therapeutics will post -0.94 EPS for the current fiscal year.

Institutional Trading of Autolus Therapeutics

A number of hedge funds have recently bought and sold shares of AUTL. Invesco Ltd. boosted its holdings in shares of Autolus Therapeutics by 53.3% during the first quarter. Invesco Ltd. now owns 32,738 shares of the company’s stock worth $51,000 after purchasing an additional 11,381 shares during the period. Wellington Management Group LLP raised its position in Autolus Therapeutics by 6.9% during the 1st quarter. Wellington Management Group LLP now owns 27,091,700 shares of the company’s stock valued at $41,992,000 after purchasing an additional 1,746,020 shares during the last quarter. Tema Etfs LLC purchased a new stake in Autolus Therapeutics in the 1st quarter worth approximately $171,000. Vident Advisory LLC bought a new stake in shares of Autolus Therapeutics in the 1st quarter worth approximately $241,000. Finally, Armistice Capital LLC grew its position in shares of Autolus Therapeutics by 19.6% in the 1st quarter. Armistice Capital LLC now owns 11,000,000 shares of the company’s stock worth $17,050,000 after buying an additional 1,800,000 shares during the last quarter. Institutional investors own 72.83% of the company’s stock.

About Autolus Therapeutics

(Get Free Report)

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.

Read More